The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2026 | How pathologic response shapes post-operative decision-making in resectable NSCLC
Brendon Stiles, MD, Albert Einstein College of Medicine, New York, NY, comments on the significance of pathologic response in influencing post-operative recommendations for patients. Dr Stiles highlights that a complete pathologic response can lead to a more optimistic prognosis, with a 95% five-year overall survival rate, and may even argue against the need for adjuvant therapy, although the decision ultimately depends on the patient and their oncologist. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
